Emcure Pharmaceuticals Targets Rs 1,952-Crore IPO Backed by Bain Capital

Bain Capital-backed Emcure Pharmaceuticals has priced its IPO between Rs 960 and Rs 1,008 per share for a total of Rs 1,952 crore. The IPO includes a fresh issue of Rs 800 crore and an Offer For Sale by existing shareholders. The company plans to use the proceeds to repay debt and for general corporate purposes.

Emcure Pharmaceuticals, supported by Bain Capital, has announced a price range of Rs 960 to Rs 1,008 per share for its upcoming Initial Public Offering (IPO) worth Rs 1,952 crore.

The IPO, open to public subscription from July 3 to 5, includes a fresh issuance of Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore equity shares totaling Rs 1,152 crore by existing shareholders, including promoter Satish Mehta and Bain Capital affiliate BC Investments IV Ltd.

Proceeds from the new issue will go towards debt repayment and general corporate purposes. The offering has a market capitalization pegged at over Rs 19,000 crore post-issue, with listing expected on BSE and NSE on July 10.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)